Press release archive
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
ViiV Healthcare Announces CHMP positive opinion to lower the age and weight limit for Tivicay® (dolutegravir) in children and adolescents living with HIV in Europe
The CHMP has adopted a positive opinion to reduce the weight and age limit for the treatment of HIV with Tivicay.
-
GSK submits regulatory application in Japan for belimumab in systemic lupus erythematosus
Belimumab is a human monoclonal antibody that selectively targets B-lymphocyte stimulator an important factor in the survival of B cells.
-
GSK opens new global vaccines R&D center in Rockville, MD, USA
New state-of-the-art facility will house 450 scientists and support staff, creating up to 200 new jobs.
-
Dominique Limet to step down as CEO of ViiV Healthcare; Deborah Waterhouse to succeed him
After seven years as CEO of ViiV Healthcare, Dr Dominique Limet will step down at the end of March 2017.
-
Relvar® Ellipta® 100/25 mcg gains approval in Japan for use in patients with COPD
Relvar is a combination of the inhaled corticosteroid, fluticasone furoate, and the long-acting beta2 agonist, vilanterol ‘VI’.
-
GSK files EU regulatory submission for once-daily closed triple combination therapy FF/UMEC/VI for patients with COPD
The filing by GSK of a regulatory submission closed triple combination therapy FF/UMEC/VI 100/62.5/25 mcg for patients with COPD.
-
GSK announces EU regulatory submission of candidate vaccine for prevention of shingles - Follows regulatory submissions in US and Canada
Tthe regulatory submission of a MMA to the EMA seeking approval for ShingrixTM.
-
GSK starts phase III programme with daprodustat for anaemia associated with chronic kidney disease
The start of a phase III development programme investigating daprodustat as a treatment for anaemia associated with CKD.
-
GSK announces phase lll study of mepolizumab meets co-primary endpoints and all secondary endpoints in patients with eosinophilic granulomatosis with polyangiitis
Both co-primary endpoints and all secondary endpoints were met in a pivotal phase III study.
-
GSK files regulatory submission in US for once-daily closed triple combination therapy FF/UMEC/VI for patients with COPD
COPD is a disease of the lungs that includes chronic bronchitis, emphysema or both.
-
GSK receives FDA approval for expanded indication for FluLaval® Quadrivalent (Influenza Vaccine) for infants 6 months and older
An approval from the US Food and Drug Administration’s (FDA) Center
-
ViiV Healthcare launches phase III programme to evaluate a long-acting, injectable HIV treatment regimen
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders
-
GSK announces new data from phase III studies of sirukumab in adult patients with moderately to severely active rheumatoid arthritis
Sirukumab is being co-developed as part of a collaboration with Janssen Biologics (Ireland) [Janssen].
-
GSK’s Benlysta® (belimumab) shows sustained benefits in patients with SLE
GSK today announced results from a 7-year safety and efficacy continuation study for Benlysta® (belimumab).
-
GSK leads Access to Medicine Index 2016
GSK has today been ranked first in the Access to Medicine Index for the fifth consecutive time.
-
GSK announces positive results in fourth consecutive pivotal trial of Benlysta® (belimumab) in SLE
Data in Japan, China and South Korea will form basis of new regulatory submissions for Benlysta
-
GSK statement in response to New York Times article on China
These matters relating to our operations in China were deeply disappointing to GSK.
-
GSK presents new data for shingles candidate vaccine at IDWeek scientific conference
GSK today announced new data for its shingles candidate vaccine ShingrixTM.
-
Results Announcement for the third quarter 2016
GSK delivers sales growth, improved cash flow and sustained pipeline progression in Q3.
-
GSK announces US regulatory submission of candidate vaccine for prevention of shingles
Regulatory submissions in the EU and Canada remain on track for 2016
